ライフサイエンスコーパス: decompensation

1 rtality and eight for postoperative clinical decompensation).

2 artery occlusion, macular hole, and corneal decompensation).

3 n males, erasure leads to permanent X dosage decompensation.

4 ic and functional protection against cardiac decompensation.

5 Gq and CaMKIIdelta recapitulates hypertrophy decompensation.

6 mainly from complications related to hepatic decompensation.

7 XO females, like XY males, develop X dosage decompensation.

8 diplopia, motility disturbances, and corneal decompensation.

9 s despite SVR, indicating persistent risk of decompensation.

10 ting may improve the risk of detecting early decompensation.

11 17 (43.6%) relapsed and one (2.6%) developed decompensation.

12 se (SVR) to therapy, remain at risk of liver decompensation.

13 D to CABG were progressive symptoms or acute decompensation.

14 tructural remodelling, protecting from organ decompensation.

15 ning no increased risk of developing corneal decompensation.

16 ly ill cirrhosis patients admitted for acute decompensation.

17 ) signaling pathways in regulating beta-cell decompensation.

18 interval [CI]: 9%-17%) patients developed a decompensation.

19 sulin-producing capacity is termed beta-cell decompensation.

20 isplacement of the IOL and secondary corneal decompensation.

21 ammation that contributes to cardiomyopathic decompensation.

22 ues of all four variables were predictive of decompensation.

23 e used to develop models to predict clinical decompensation.

24 d albumin was the best predictor of clinical decompensation.

25 ng systems that identify patients at risk of decompensation.

26 h rapid progression to cirrhosis and hepatic decompensation.

27 t failure events in time to prevent clinical decompensation.

28 palmar plantar erythrodysesthesia, and liver decompensation.

29 lebs may induce corneal dissection, and even decompensation.

30 which could affect determination of risk for decompensation.

31 y inevitably remodels, leading to functional decompensation.

32 ptosis inhibition to prevent cardiomyopathic decompensation.

33 29% had at least 1 previous episode of liver decompensation.

34 and those with cirrhosis and severe hepatic decompensation.

35 not cost-effective among those with hepatic decompensation.

36 o adverse events, patient decision, or liver decompensation.

37 estoration of liver mass, and leads to liver decompensation.

38 nts and in those with no previous history of decompensation.

39 provement after PTRAS in patients with acute decompensation.

40 -treat population and are at risk of hepatic decompensation.

41 s died, mainly from complications of hepatic decompensation.

42 ned absence to regeneration arrest and liver decompensation.

43 d ventricular contraction during hemodynamic decompensation.

44 nd to be independently predictive of hepatic decompensation.

45 .17; P = 0.01) were associated with death or decompensation.

46 performed at the time of the patient's acute decompensation.

47 ted with systemic inflammation and cirrhosis decompensation.

48 based on the short-term likelihood of liver decompensations.

49 he follow-up was 0.010 eye-year (EY); cornea decompensation, 0.001 EY; ocular hypertension, 0.008 EY;

50 sease and Child-Turcotte-Pugh scores (HR for decompensation, 0.55; 95% CI, 0.39-0.78), and death (HR,

51 hite, 60% genotype 1a, 30% METAVIR F3-F4, 4% decompensation, 11% cholestatic recurrence, 7% had kidne

52 (19.6% versus 8.8%; P = 0.046), and hepatic decompensation (16.7% versus 6.9%; P = 0.049) were great

53 nts with cirrhosis with no evidence of acute decompensation, 20 patients with septic shock but no cir

54 robability of hospital admission for hepatic decompensation, 37% and 54%; and survival rates, 77% and

55 The indications were corneal decompensation (39.4%), malpositioned AC IOL (28.9%), uv

56 Sixty-two (29%) of 213 patients developed decompensation: 46 (21.6%) ascites, 6 (3%) VH, 17 (8%) H

57 s (13.9% versus 9.7%; P = 0.606), or hepatic decompensation (8.3% versus 9.7%; P = 0.778) between sim

58 ections (8% vs. 6%; P = 0.47), and events of decompensation (9% vs. 10%; P = 0.78) occurred at simila

59 nts with cirrhosis hospitalized for an acute decompensation (AD) and organ failure are at risk for im

60 ver failure (ACLF) is characterized by acute decompensation (AD) of cirrhosis, organ failure(s), and

61 HBV associated cirrhotic patients with acute decompensation (AD) were enrolled.

62 ACLF) in cirrhosis is characterized by acute decompensation (AD), organ failure(s), and high short-te

63 correlate with acute clinical heart failure decompensation (ADHF) and related adverse clinical outco

64 etry, leads to an increased risk for corneal decompensation after phacoemulsification in patients wit

65 k of 3- and 5-year mortality and of clinical decompensation after surgery for HCC.

66 V), abdominal pain, infection, acute hepatic decompensation (AHD) and acute kidney injury (AKI).

67 currence of periprocedural acute hemodynamic decompensation (AHD) in patients undergoing radiofrequen

68 ]) were each associated with higher rates of decompensation among co-infected patients.

69 Regression analysis revealed a lower risk of decompensation among statin users with cirrhosis due to

70 had acute kidney injury as their reason for decompensation and 23.6% had an infection.

71 The mechanisms underlying this decompensation and brain injury are poorly understood.

72 ing date of HCV therapy to the first hepatic decompensation and death due to any cause.

73 The time from diagnosis to the first liver decompensation and death from liver disease, as well as

74 (CT) images, allows prediction of cirrhosis decompensation and death.

75 ine CT images allows prediction of cirrhosis decompensation and death.

76 with a more than 40% lower risk of cirrhosis decompensation and death.

77 sal normoxic conditions and in acute cardiac decompensation and enhanced mortality during transient h

78 Transgenic mice were protected from decompensation and fibrosis following long-term TAC.

79 l participants were hospitalized for cardiac decompensation and had a left ventricular ejection fract

80 the downstream signaling defects leading to decompensation and heart failure are poorly understood.

81 d its related complications, such as hepatic decompensation and hepatocellular carcinoma (HCC).

82 response (SVR) have a lower risk of hepatic decompensation and hepatocellular carcinoma (HCC).

83 of prespecified clinical outcomes of hepatic decompensation and hepatocellular carcinoma across indiv

84 are an option for patients with hemodynamic decompensation and high bleeding risk.

85 content in the heart was protective against decompensation and hypertrophic cardiomyopathy following

86 absence of miR-22 sensitized mice to cardiac decompensation and left ventricular dilation after long-

87 Hepatic decompensation and liver cancer will continue to increas

88 values during follow-up to predict clinical decompensation and liver-related death/liver transplant

89 Statin use decreases the risk of decompensation and mortality in patients with cirrhosis

90 ortal hypertension (CSPH; HVPG >/= 10 mmHg), decompensation and mortality.

91 he association of the LSN score with hepatic decompensation and overall survival.

92 We investigated the effects of statins on decompensation and survival times in patients with compe

93 e progression and to avoid or delay clinical decompensation and the need for liver transplantation.

94 kedly reduces the incidence of liver-related decompensation and the overall mortality in HIV/HCV-coin

95 appeared to delay the occurrence of hepatic decompensation and to improve survival.

96 ith biopsy, the adjusted subhazard ratio for decompensations and 95% confidence interval (95% CI) by

97 Thus, we aimed at evaluating the risk of decompensations and death among human immunodeficiency v

98 LS predicts the development of hepatic decompensations and liver-related mortality in HIV/HCV-c

99 Survivors remain at risk of metabolic decompensations and severe long term complications, nota

100 as associated with a marked decrease in HCC, decompensation, and bacterial infection incidences.

101 neonatal encephalopathy, episodic metabolic decompensation, and chronic amino acid imbalances.

102 The risk for HCC, liver decompensation, and death in patients with liver cirrhos

103 n and reduction in hepatic fibrosis, hepatic decompensation, and liver-related mortality.

104 es such as hepatocellular carcinoma, hepatic decompensation, and mortality among US veterans with hep

105 ent of hepatocellular carcinoma (HCC), liver decompensation, and overall survival.

106 ates indicate patients with cirrhosis, prior decompensation, and previous protease inhibitor treatmen

107 reased HCC incidence were cirrhosis, hepatic decompensation, and soluble serum intercellular adhesion

108 left ventricular hypertrophy, its subsequent decompensation, and the transition to heart failure.

109 The effect of diabetes on cirrhosis, its decompensation, and their time relationship in chronic h

110 The impact of diabetes on cirrhosis, its decompensation, and their time relationship in patients

111 months, 6 patients died, 8 experienced liver decompensations, and 7 were diagnosed with hepatocellula

112 urthermore, whereas cirrhosis and subsequent decompensation are accepted hard clinical endpoints, fib

113 The molecular events that drive hypertrophy decompensation are incompletely understood.

114 Clinical endpoints defined as hepatic decompensation (ascites, encephalopathy, and variceal bl

115 may signal the beginnings of cardiovascular decompensation associated with haemorrhage.

116 lan-Meier probability of episodes of hepatic decompensation at 1 and 2 years was 41% and 57%; probabi

117 A classic pattern of beta-cell decompensation before diagnosis was noted only in the fa

118 osis (n = 550), a first diagnosis of hepatic decompensation before or within 12 months after initial

119 analysis, the median duration of endothelial decompensation before the regraft was 21 days (range, 2-

120 initiated ART at entry, for incident hepatic decompensation between 1996 and 2010.

121 , fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhag

122 e gained from following patients after acute decompensation, but a more important reason is that by f

123 RT significantly reduced the rate of hepatic decompensation by 28%-41% on average.

124 gest that CaMKIIdelta contributes to cardiac decompensation by enhancing RyR2-mediated sarcoplasmic r

125 pia and myopic astigmatism, although corneal decompensation can occur after implantation.

126 ents in 2010 could reduce risk of cirrhosis, decompensation, cancer, and liver-related deaths by 16%,

127 Despite progressive cardiac remodeling and decompensation, chronic CRT continues to provide hemodyn

128 d to estimate hazard ratios (HRs) of hepatic decompensation, comparing initiation of ART to noninitia

129 However, the risk of liver decompensation (DC) among HIV/HCV-coinfected patients wi

130 r aim was to identify predictors of clinical decompensation (defined as the development of ascites, v

131 Incident hepatic decompensation, determined by diagnoses of ascites, spon

132 Death from causes secondary to liver decompensation did not differ significantly between pati

133 mplications (eg, retinal detachment, corneal decompensation, dislocated intraocular lens [IOL]).

134 ed PlasmaLyte solution in limiting metabolic decompensation due to graft preparation.

135 ers a potential future therapy for metabolic decompensation due to mitochondrial CI dysfunction.

136 ated cirrhosis, 40% (129 of 326) experienced decompensation during a median follow-up period of 4.22

137 ermates experienced rapid and marked cardiac decompensation during this same challenge.

138 s, proptosis, tube erosion, failure, corneal decompensation, endophthalmitis, and visual loss are all

139 there is a low probability of severe corneal decompensation, even in patients with a low endothelial

140 d probability of survival from first hepatic decompensation event compared with a 59.8% (95% CI, 56.3

141 sted veterans from the time of first hepatic decompensation event in multivariable survival models (h

142 ruses (HBV, HCV, HDV, respectively) on liver decompensation events (ascites, variceal bleeding, encep

143 We observed 645 hepatic decompensation events in 46 444 person-years of follow-u

144 sociated with a high rate of death and liver decompensation events in HIV-infected patients on ART.

145 r-cardioverter-defibrillator in the Reducing Decompensation Events Utilizing Intracardiac Pressures i

146 LD, defined as those with at least two liver decompensation events, were included in the analysis.

147 lated complications and 26 developed hepatic decompensation events.

148 r events (defined as liver-related deaths or decompensations, excluding HCC) and used Poisson regress

149 nderwent DMEK for graft failure with corneal decompensation following DSAEK were analyzed; 15 eyes wi

150 s: severe alcoholic hepatitis as first liver decompensation (Group 1), alcoholic cirrhosis with >/=6

151 The incidence and determinants of hepatic decompensation have been incompletely examined among pat

152 fected patients had a higher rate of hepatic decompensation (hazard ratio [HR] accounting for competi

153 Statin users had a lower risk of decompensation (hazard ratio [HR], 0.55; 95% confidence

154 ce interval: 1.19, 3.23; P=.007) and hepatic decompensation (hazard ratio, 1.51; 95% confidence inter

155 osis, HCV eradication reduced risk for liver decompensation, HCC, and death, regardless of whether th

156 B surface antigen (HBsAg), prevalent hepatic decompensation (HD), hepatocellular carcinoma (HCC), and

157 ression to hepatocellular carcinoma, hepatic decompensation (hepatic encephalopathy, esophageal varic

158 elated death, liver transplantation, hepatic decompensation, hepatocellular carcinoma) were observed

159 nical outcomes (liver-related death, hepatic decompensation, hepatocellular carcinoma, liver transpla

160 e patients present clinically with metabolic decompensation; however, this primary pathologic process

161 .015; 95% CI, 1.393-2.915; P < .001) and its decompensation (HR = 1.792; 95% CI, 1.192-2.695; P = .00

162 erval [CI], 0.19-0.43; P < .001) and hepatic decompensation (HR, 0.26; 95% CI, 0.17-0.39; P < .001).

163 than patients with stage 1 disease for liver decompensation (HR, 2.82; 95% CI, 1.73-4.59; P < .001) o

164 =2.505; 95% CI=1.609-3.897; P<0.001) and its decompensation (HR=3.560; 95% CI=1.526-8.307; P=0.003).

165 fibrosis can cause IOL dislocation, corneal decompensation, hypotony, and retinal detachment, monito

166 f arrest was hypotension in 67%, respiratory decompensation in 44%, and arrhythmia in 19%.

167 ological features point to periodic systemic decompensation in ATP1A3-expressing organs.

168 Obesity increases the risk of clinical decompensation in cirrhosis, possibly by increasing port

169 4 score >5.88-and time to onset of cirrhotic decompensation in electronic medical records.

170 rate of hospital admission for heart failure decompensation in follow-up (HR, 1.66; 95% CI, 1.27-2.18

171 novel strategy for treating SCD and cardiac decompensation in HF.

172 ects varied widely from acute neurometabolic decompensation in late infancy to subtle neurological si

173 lost >/= 3 Snellen lines because of corneal decompensation in one and angle-closure glaucoma in the

174 Acute decompensation in patients with chronic liver disease, r

175 Mortality after acute decompensation in patients with heart failure with prese

176 graft rejection (0.6% vs. 3.1%), endothelial decompensation in the absence of documented rejection (1

177 nagement, children commonly suffer metabolic decompensation in the context of catabolic stress associ

178 estimated disease with a high risk for acute decompensation in the perioperative period.

179 ents, such as those with acute heart failure decompensation in the setting of clinically evident hypo

180 e in identifying patients at risk of hepatic decompensation in the transplant setting.

181 ut advanced fibrosis are at very low risk of decompensations in the short term; deferral of HCV thera

182 ons that may further precipitate other liver decompensations including acute-on-chronic liver failure

183 perative CCT, the odds of developing corneal decompensation increased 1.7 times.

184 Galpha(z) to both major aspects of beta-cell decompensation: insufficient beta-cell function and mass

185 No corneal decompensation, iritis, secondary glaucoma, or pupillary

186 Postoperative liver decompensation (LD) is the most representative and least

187 f patients with HF with preserved EF reduced decompensation leading to hospitalization compared with

188 modynamically guided HF management decreases decompensation leading to hospitalization.

189 ction is crucial, because unexpected corneal decompensation leads to dissatisfied patients.

190 es of 1/60 OD and 6/18 OS, bilateral corneal decompensation, lens opacities and raised intraocular pr

191 to assess the influence of these factors on decompensation, liver transplantation, and death.

192 ted with an 8.4-fold increased risk of liver decompensations, liver transplantations, or deaths (P <

193 Decompensation may occur abruptly and catastrophically b

194 pecular microscopy, but occasionally corneal decompensation may occur.

195 cirrhosis, statin use decreased the risk of decompensation, mortality, and HCC in a dose-dependent m

196 termine the effect of statin use on rates of decompensation, mortality, and HCC in HBV-, HCV-, and al

197 e association between statin use and risk of decompensation, mortality, and HCC were estimated.

198 osis without ACLF (n = 9), cirrhosis without decompensation (n = 17), or acute liver failure (n = 23)

199 h a reduced risk of liver cirrhosis, hepatic decompensation, need for liver transplantation, and both

200 an SVR (11.9%) (P = .03) or developed liver decompensation (none vs 7.1% without an SVR; P = .009).

201 l model recapitulates the cardio-respiratory decompensation observed in humans, and that EVHP appears

202 Death or hemodynamic decompensation occurred in 13 of 506 patients (2.6%) in

203 Six (11%) patients died, and hepatic decompensation occurred in 22% with advanced fibrosis an

204 Liver decompensation occurred more frequently in HCV patients

205 No episodes of clinical decompensation occurred.

206 ndan-treatment on MPO in patients with acute decompensation of chronic heart failure over a one week

207 In acute decompensation of chronic heart failure, the change in t

208 to adjust therapy during hospitalization for decompensation of chronic heart failure.

209 t beta-blockers are more suitable to prevent decompensation of cirrhosis in patients with CSPH than i

210 NGAL in 429 patients hospitalized for acute decompensation of cirrhosis in the EASL-CLIF Acute-on-Ch

211 (HR = 0.53; 95% CI = 0.29-0.98), and further decompensation of cirrhosis occurred in 52% versus 72% (

212 Patients had either ACLF (n = 41), acute decompensation of cirrhosis without ACLF (n = 9), cirrho

213 s with advanced HCC, female gender, clinical decompensation of cirrhosis, and multinodular tumor are

214 re (ACLF) syndrome is characterized by acute decompensation of cirrhosis, organ failure, and high 28-

215 reduce the risk of rebleeding and of further decompensation of cirrhosis, thus contributing to a bett

216 y volunteers) of PGE2 in patients with acute decompensation of cirrhosis.

217 ent in noncritically ill patients with acute decompensation of cirrhosis.

218 notion that both measures are indicators of decompensation of heterophoria.

219 ype of glaucoma can cause angle closure with decompensation of intraocular pressure secondary to fibr

220 is of cirrhosis, done by TE, and no previous decompensation of liver disease.

221 Median times to decompensation of patients at high (1.76 years, n = 48),

222 lowing cataract extraction and LASIK include decompensation of pre-existing strabismus, new-onset acc

223 procedures, the leading cause of diplopia is decompensation of pre-existing strabismus.

224 No patients developed decompensation of their liver disease, although one pati

225 - and 5-year mortality and/or early clinical decompensation) of patients with HCC and compensated cir

226 r the third year), without evidence of liver decompensation; only 1 lost HBsAg (6%).

227 patients with a vWF-Ag >315% median time to decompensation or death was 32 months compared with 59 m

228 ecreased in the serum of patients with acute decompensation or ESLD (<30 mg/dl) and appears to have a

229 the estimated risk of progression to hepatic decompensation or hepatocellular carcinoma was 37.2% in

230 TE and HVPG to predict the first LRE (liver decompensation or hepatocellular carcinoma).

231 and liver-related events (LREs), defined as decompensation or hepatocellular carcinoma, whichever oc

232 rongest predictors of progression to hepatic decompensation or hepatocellular carcinoma.

233 ents are diagnosed in late stages when liver decompensation or liver cancer develops.

234 ost effective treatment for those with liver decompensation or small hepatocellular carcinoma.

235 when admitted to hospital for acute cardiac decompensation or stroke.

236 d tears, all in the UNC group, with no acute decompensations or deaths and only 1 patient who require

237 The primary outcome was death or hemodynamic decompensation (or collapse) within 7 days after randomi

238 continuation due to tumor progression, liver decompensation, or adverse effects.

239 le cause for liver disease, signs of hepatic decompensation, or another significant nonhepatic diseas

240 by death, hepatocellular carcinoma, hepatic decompensation, or, for those with bridging fibrosis at

241 y recognized syndrome characterized by acute decompensation, organ failure(s) and high short-term mor

242 osis as well as in cirrhosis associated with decompensation other than sepsis, such as bleeding and a

243 an increased risk of liver cirrhosis and its decompensation over time.

244 an increased risk of liver cirrhosis and its decompensation over time.

245 Patients with hepatic decompensation, particularly those with Child-Turcotte-P

246 nsating phase of RVH tissues but was lost in decompensation phase of RVH.

247 sition from compensating phase of RVH toward decompensation phase of RVH.

248 increased the risk of postoperative clinical decompensation (pooled OR: 3.04; 95% CI: 2.02-4.59).

249 as the only significant predictor of corneal decompensation postoperatively (P < .001).

250 1.2 mg/dL, absence of cirrhosis, and hepatic decompensation predicted SVR at 12 weeks.

251 Of borderline significance is a decreased decompensation rate in alcohol-related cirrhosis.

252 Statin use decreases the decompensation rate in both HBV- and HCV-related cirrhos

253 this condition and may worsen cardiovascular decompensation related through negative inotropic and hy

254 had a significantly reduced rate of hepatic decompensation relative to noninitiators (HR = 0.72; 95%

255 death, cardiac transplantation, or clinical decompensation requiring a move to sea level, were deter

256 mission for decompensated HF, or clinical HF decompensation requiring either parenteral HF therapy or

257 least 8% for 6 months or sustained metabolic decompensation requiring insulin.

258 ac transplantation in 18 (17%), and clinical decompensation requiring move to sea level in 13 (13%).

259 ular assist devices and may lead to clinical decompensation requiring surgical correction.

260 ned lens fragments and can evolve to corneal decompensation requiring transplantation.

261 of RhoGEF12 deficiency protects from cardiac decompensation, resulting in significantly increased lon

262 erged as an effective way to eliminate acute decompensation risk.

263 occurred in 49.9% of cases, including liver decompensation, severe infections in 10.4%, and death in

264 tical illness may represent a stress-related decompensation syndrome mediated by neural, endocrine, b

265 han 1000 copies/mL still had higher rates of decompensation than HCV-monoinfected patients (HR, 1.44

266 with HIV and HCV had higher rates of hepatic decompensation than HCV-monoinfected patients.

267 Patients with HF may experience frequent decompensations that require hospitalization despite int

268 to minimize the duration of central corneal decompensation, the visual outcomes with secondary DMEK

269 ns in all these indications but also further decompensation (variceal bleeding, hepatorenal syndrome)

270 ents with a baseline LS < 40 kPa developed a decompensation versus 17 (29%) out of 58 with LS >/= 40

271 Two (4.6%) patients with SVR developed liver decompensation vs 33 (26.8%) individuals without SVR (P

272 The incidence of decompensation was 6.7 cases per 100 person-years (95% C

273 Ventricular decompensation was characterized by a 62% reduction in a

274 Hepatic decompensation was defined as the first occurrence of 1

275 The incidence of hepatic decompensation was greater among co-infected than monoin

276 The incidence rate of hepatic decompensation was higher in patients with human immunod

277 with HIV/HCV-infected patients, the rate of decompensation was increased among HIV/HBV/HCV-infected

278 Liver decompensation was less frequent among patients given en

279 The actuarial probability of liver decompensation was lower in the enoxaparin group (P < .0

280 The lowered risk of decompensation was of borderline significance among stat

281 Incident decompensation was the most common serious adverse event

282 Factors independently associated with decompensation were Child-Turcotte-Pugh (CTP) class B ve

283 (ECD) in patient 2, but no signs of corneal decompensation were detected.

284 Cirrhosis and decompensation were determined from International Classi

285 Rates of decompensation were higher for co-infected patients with

286 On multivariate analysis, 3 predictors of decompensation were identified: HVPG (hazard ratio [HR],

287 Factors independently associated with liver decompensation were non-SVR (hazard ratio [HR], 8.1; 95%

288 consecutive DMEK operations for endothelial decompensation were reviewed; 97 eyes of 84 patients met

289 nd low (6.14 years, n = 152) risk of hepatic decompensation were significantly different (P < .001).

290 SAEs associated with hepatic decompensation were the most frequent, with 26 SAEs occu

291 and ophthalmologists to detect heterophoria decompensation, were correlated with aligning prism (ass

292 striction (TAC), they manifest rapid cardiac decompensation, which is accompanied by excess cardiac f

293 chondrial protein oxidation, and hypertrophy decompensation, which were attenuated by CaMKIIdelta del

294 n compensatory hypertrophy and absent during decompensation will provide molecular targets for preven

295 However, unrelenting stress can lead to decompensation with development of pathologic illness.

296 episodes, patients may suffer from metabolic decompensation with dysfunction of liver, skeletal- and

297 up of patients, which can result in clinical decompensation with overt heart failure, arrhythmias, an

298 cohort until development of cirrhosis or its decompensation, withdrawal from insurance, or December 2

299 abetes until development of cirrhosis or its decompensation, withdrawal from insurance, or December 2

300 y can increase necroinflammation and hepatic decompensation without enhancing fibrosis progression.